At Hadassah Hospital Ein Kerem, symptoms improved in 11 of the 12 COVID-19 patients who were given a plasma-derived therapy developed by Kamada, an Israeli biopharmaceutical company. On average, the patients were able to go home in less than five days.
The patients, all of whom had pneumonia but were not on ventilators, were participants in a phase 1/2 clinical trial at Hadassah. They were treated with Kamada’s “passive vaccine,” comprised of a hyperimmune immunoglobulin product that provides the patient with antibodies to fight the disease.
The antibodies were harvested from recovered COVID-19 patients who volunteered to donate their plasma. The plasma donations, collected by Hadassah’s Blood Bank, were transferred to Kamada’s facilities together with doses collected by Magen David Adom.
The first patient to be given the plasma-derived therapy was treated at Hadassah in June. Two other patients were also successfully treated before the clinical trial was launched.
Five of the patients have been followed up for 21 days, two for 14 days, and the additional five patients for seven days. Plans are to monitor these patients for a total of 84 days.
In an interview with The Jerusalem Post, Kamada’s chief executive officer Amir London said that he believes his company is the first one globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19. A “plasma-derived IgG product, as developed by Kamada,” he reported, “is considered to have multiple advantages over convalescent plasma transfusion, including standardized antibody levels, higher potency, extensive viral inactivation processing, the absence of a blood-type matching requirement, smaller infusion volumes, the ability to be produced in large quantities, an expected longer shelf life, and preferred storage conditions.”
Read the full story in The Jerusalem Post.